Gland Pharma Limited (NSE:GLAND)

Gland Pharma Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	70,606	64,307	56,165	56,647	36,246	44,007
Revenue Growth	21.70%	14.50%	-0.85%	56.28%	-17.64%	27.08%
Gross Profit Gross Profit Growth	41,880	37,972	31,544	31,108	17,651	21,513
Operating Income Operating Income Growth	14,520	11,906	8,721	9,715	8,844	14,000
Net Income Net Income Growth	12,359	10,273	6,985	7,725	7,810	12,117
Earnings Per Share EPS Growth	74.88	62.28	42.40	46.89	47.43	73.64
EPS Growth	56.07%	46.89%	-9.58%	-1.14%	-35.59%	16.91%

Revenue by Geography

Chart

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
USA USA Growth	31,185	27,403	26,878	20,910	23,327
Europe Europe Growth	14,110	10,225	10,528	1,871	2,398
India India Growth	5,510	4,765	5,880	5,548	8,801
Rest of World (ROW) Rest of World (ROW) Growth	11,169	11,377	11,817	6,893	8,481
Canada Canada Growth	1,404	1,574	890.27	794.9	829.19
Australia Australia Growth	851.32	742.94	626.45	218.24	170.87
New Zealand New Zealand Growth	77.11	77.23	28.17	10.86	-
Total Total Growth	64,307	56,165	56,647	36,246	44,007

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	34,412	33,591	29,522	19,388	37,628	32,457
Total Debt Total Debt Growth	2,512	2,836	3,137	3,722	44.53	47.43
Net Cash (Debt) Net Cash Growth	31,900	30,755	26,385	15,666	37,584	32,410
Net Cash Growth	10.01%	16.56%	68.42%	-58.32%	15.96%	8.10%
Net Cash Per Share Net Cash Per Share Growth	193.29	186.45	160.15	95.10	228.22	196.97

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	10,409	10,314	9,147	9,968	3,640	7,908
Capital Expenditures CapEx Growth	-5,510	-4,908	-3,845	-3,899	-2,209	-5,113
Free Cash Flow Free Cash Flow Growth	4,899	5,406	5,302	6,069	1,430	2,794
Free Cash Flow Growth	10.59%	1.97%	-12.63%	324.27%	-48.81%	-25.71%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	59.31%	59.05%	56.16%	54.92%	48.70%	48.88%
Operating Margin	20.57%	18.52%	15.53%	17.15%	24.40%	31.81%
Pretax Margin	24.56%	22.77%	18.92%	19.99%	29.10%	36.78%
Profit Margin	17.50%	15.97%	12.44%	13.64%	21.55%	27.53%
FCF Margin	6.94%	8.41%	9.44%	10.71%	3.95%	6.35%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Nov 12, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Dividend Per Share Dividend Per Share Growth	20.000	20.000	18.000	20.000
Dividend Per Share Growth	11.11%	11.11%	-10.00%	-
Dividend Yield	0.60%	1.18%	1.13%	1.08%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov 12, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	44.27	27.20	37.56	39.35	26.74	44.38
Forward PE	36.24	26.18	27.55	29.26	17.57	35.96
P/FCF Ratio	111.63	51.69	49.48	50.08	146.03	192.42
PS Ratio	7.75	4.35	4.67	5.37	5.76	12.22

Data Source: S&P Global Market Intelligence Last updated: Nov 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 12, 2026

Data Sources Report a data error